Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
——
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's proceeds from disposition of marketable securities and other investments?
Bicara Therapeutics (BCAX) reported proceeds from disposition of marketable securities and other investments of $101M in Q1 2026.